Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "CHEMI"

813 News Found

Jubilant Biosys expands Chemistry Innovation Research Centre
Supply Chain | November 12, 2021

Jubilant Biosys expands Chemistry Innovation Research Centre

The centre has an initial capacity of 500 FTEs


Zydus ties up with CHEMI to launch Enoxaparin Sodium injection in the US
Drug Approval | August 20, 2021

Zydus ties up with CHEMI to launch Enoxaparin Sodium injection in the US

Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT


IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores
News | August 16, 2021

IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores

'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22


JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
News | August 13, 2021

JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22

Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21


JB Chemicals PAT jumps by 101% to Rs101 Cr
News | June 15, 2021

JB Chemicals PAT jumps by 101% to Rs101 Cr

The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020


Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector
News | March 08, 2021

Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector

The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.


J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr
News | February 11, 2021

J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr

The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.


Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Drug Approval | May 03, 2025

Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,


Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences
News | April 25, 2025

Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences

The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations


Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion
News | April 24, 2025

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience